Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Standard of Care (SOC) Migraine Preventive Medication
Standard of Care Migraine Preventive Medication · 1 trial · 1 indication
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is an AE that occurs or worsens after receiving investigational study drug.
| Arm | Type | Description |
|---|---|---|
| Oral SOC Migraine Preventive Medication | ACTIVE_COMPARATOR | Oral standard of care (SOC) medication recognized as safe and effective for the prevention of migraine, based on investigator's judgement in consultation with the participant. |
| Atogepant 60 mg | EXPERIMENTAL | Atogepant 60 mg tablet taken orally, once daily for 52 weeks. |
| Name | Type | Description |
|---|---|---|
| Standard of Care (SOC) Migraine Preventive Medication | DRUG | Standard of care medication selected based on investigator's judgement, recognized as safe and effective for the prevention of migraine. |
| Atogepant | DRUG | Atogepant tablets taken orally, once daily for 52 weeks. |
Inclusion Criteria: * Written informed consent and participant privacy information (e.g., written authorization for use and release of health and research study information) obtained from the participant prior to initiation of any study-specific procedures. * Participant is a candidate to be prescr...